Is ALLR or PCSA more profitable?

Allarity Therapeutics' return on equity of -109.94% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Allarity Therapeutics N/A -109.94% -47.27% Heatwurx N/A -281.31% -200.80%

Which has higher valuation and earnings, PCSA or CLRB?

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$9.29 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is PCSA or CLRB more profitable?

Heatwurx's return on equity of -281.31% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Cellectar Biosciences N/A -349.24% -153.18%

Is PCSA or LPCN more profitable?

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Lipocine -571.18% -66.70% -59.39%

Which has stronger earnings & valuation, PCSA or RKTO?

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heatwurx N/A N/A -$13.56M -$9.29 N/A Rocket One Inc. Common Stock N/A N/A -$12.47M -$0.80 N/A

Is PCSA or RKTO more profitable?

Rocket One Inc. Common Stock's return on equity of -165.25% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Heatwurx N/A -281.31% -200.80% Rocket One Inc. Common Stock N/A -165.25% -143.61%

Is CELU or PCSA more profitable?

Heatwurx has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Heatwurx's return on equity. Company Net Margins Return on Equity Return on Assets Celularity -345.45% N/A -77.94% Heatwurx N/A -281.31% -200.80%

Heatwurx (PCSA) Competitors

$2.16 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$2.13 -0.03 (-1.44%)

As of 07/2/2026 07:44 PM Eastern

Compare

PCSA vs. ALLR, CLRB, LPCN, RKTO, and CELU

Should you buy Heatwurx stock or one of its competitors? MarketBeat compares Heatwurx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heatwurx include Allarity Therapeutics (ALLR), Cellectar Biosciences (CLRB), Lipocine (LPCN), Rocket One Inc. Common Stock (RKTO), and Celularity (CELU). These companies are all part of the "pharmaceutical products" industry.

How does Heatwurx compare to Allarity Therapeutics?

Allarity Therapeutics (NASDAQ:ALLR) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Heatwurx had 1 more articles in the media than Allarity Therapeutics. MarketBeat recorded 3 mentions for Heatwurx and 2 mentions for Allarity Therapeutics. Heatwurx's average media sentiment score of 1.00 beat Allarity Therapeutics' score of 0.60 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Allarity Therapeutics	Positive
Heatwurx	Positive

Allarity Therapeutics has higher revenue and earnings than Heatwurx. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allarity Therapeutics	$320K	65.13	-$11.23M	-$0.72	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

11.5% of Allarity Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 0.2% of Allarity Therapeutics shares are held by insiders. Comparatively, 3.5% of Heatwurx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Allarity Therapeutics presently has a consensus target price of $10.25, indicating a potential upside of 682.44%. Heatwurx has a consensus target price of $25.00, indicating a potential upside of 1,057.41%. Given Heatwurx's higher probable upside, analysts clearly believe Heatwurx is more favorable than Allarity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Allarity Therapeutics' return on equity of -109.94% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allarity Therapeutics	N/A	-109.94%	-47.27%
Heatwurx	N/A	-281.31%	-200.80%

Allarity Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Summary

Heatwurx beats Allarity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Heatwurx compare to Cellectar Biosciences?

Heatwurx (NASDAQ:PCSA) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,057.41%. Cellectar Biosciences has a consensus price target of $11.00, indicating a potential upside of 291.46%. Given Heatwurx's higher possible upside, research analysts plainly believe Heatwurx is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Heatwurx's return on equity of -281.31% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Cellectar Biosciences	N/A	-349.24%	-153.18%

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

In the previous week, Heatwurx had 1 more articles in the media than Cellectar Biosciences. MarketBeat recorded 3 mentions for Heatwurx and 2 mentions for Cellectar Biosciences. Heatwurx's average media sentiment score of 1.00 beat Cellectar Biosciences' score of 0.47 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Positive
Cellectar Biosciences	Neutral

Heatwurx has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Heatwurx beats Cellectar Biosciences on 9 of the 13 factors compared between the two stocks.

How does Heatwurx compare to Lipocine?

Heatwurx (NASDAQ:PCSA) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Heatwurx has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Lipocine	-571.18%	-66.70%	-59.39%

In the previous week, Heatwurx had 3 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Heatwurx and 0 mentions for Lipocine. Heatwurx's average media sentiment score of 1.00 beat Lipocine's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Positive
Lipocine	Neutral

Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,057.41%. Lipocine has a consensus price target of $15.00, indicating a potential upside of 527.62%. Given Heatwurx's higher probable upside, research analysts clearly believe Heatwurx is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Heatwurx has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Lipocine has higher revenue and earnings than Heatwurx. Lipocine is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Lipocine	$1.98M	9.95	-$9.63M	-$1.88	N/A

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 9.1% of Lipocine shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by insiders. Comparatively, 6.4% of Lipocine shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Heatwurx and Lipocine tied by winning 8 of the 16 factors compared between the two stocks.

How does Heatwurx compare to Rocket One Inc. Common Stock?

Heatwurx (NASDAQ:PCSA) and Rocket One Inc. Common Stock (NASDAQ:RKTO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Heatwurx had 3 more articles in the media than Rocket One Inc. Common Stock. MarketBeat recorded 3 mentions for Heatwurx and 0 mentions for Rocket One Inc. Common Stock. Heatwurx's average media sentiment score of 1.00 beat Rocket One Inc. Common Stock's score of 0.00 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Positive
Rocket One Inc. Common Stock	Neutral

Rocket One Inc. Common Stock is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
Rocket One Inc. Common Stock	N/A	N/A	-$12.47M	-$0.80	N/A

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 7.1% of Rocket One Inc. Common Stock shares are owned by institutional investors. 3.5% of Heatwurx shares are owned by company insiders. Comparatively, 6.9% of Rocket One Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Rocket One Inc. Common Stock's return on equity of -165.25% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
Rocket One Inc. Common Stock	N/A	-165.25%	-143.61%

Heatwurx has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Rocket One Inc. Common Stock has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market.

Heatwurx currently has a consensus target price of $25.00, indicating a potential upside of 1,057.41%. Rocket One Inc. Common Stock has a consensus target price of $5.00, indicating a potential upside of 463.06%. Given Heatwurx's higher probable upside, analysts plainly believe Heatwurx is more favorable than Rocket One Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rocket One Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Heatwurx beats Rocket One Inc. Common Stock on 6 of the 11 factors compared between the two stocks.

How does Heatwurx compare to Celularity?

Celularity (NASDAQ:CELU) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership.

Celularity has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Heatwurx has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market.

In the previous week, Heatwurx had 3 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Heatwurx and 0 mentions for Celularity. Heatwurx's average media sentiment score of 1.00 beat Celularity's score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Celularity	Neutral
Heatwurx	Positive

Celularity presently has a consensus price target of $6.00, indicating a potential upside of 868.21%. Heatwurx has a consensus price target of $25.00, indicating a potential upside of 1,057.41%. Given Heatwurx's higher possible upside, analysts clearly believe Heatwurx is more favorable than Celularity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.0% of Celularity shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 3.5% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Heatwurx has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Heatwurx	N/A	-281.31%	-200.80%

Heatwurx has lower revenue, but higher earnings than Celularity. Heatwurx is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.68	-$91.72M	-$3.33	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Summary

Heatwurx beats Celularity on 7 of the 13 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.98M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-0.23	20.06	28.02	24.70
Price / Sales	N/A	360.33	540.37	99.49
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	0.88	4.32	10.96	6.46
Net Income	-$13.56M	$64.45M	$3.57B	$337.01M
7 Day Performance	16.13%	2.97%	2.12%	1.69%
1 Month Performance	-14.29%	6.83%	5.25%	3.81%
1 Year Performance	-55.23%	29.07%	33.29%	23.90%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	4.074 of 5 stars	$2.16 flat	$25.00 +1,057.4%	-55.2%	$5.98M	N/A	N/A	20	Positive News Gap Down High Trading Volume
ALLR Allarity Therapeutics	1.8753 of 5 stars	$1.30 +2.4%	$10.25 +688.5%	+30.2%	$20.21M	$320K	N/A	10
CLRB Cellectar Biosciences	4.3677 of 5 stars	$2.53 +2.2%	$11.00 +335.6%	-41.7%	$19.74M	N/A	N/A	10	News Coverage
LPCN Lipocine	3.2942 of 5 stars	$2.46 +3.4%	$15.00 +509.8%	-26.9%	$19.62M	$1.98M	N/A	10
RKTO Rocket One Inc. Common Stock	1.7768 of 5 stars	$0.95 +8.7%	$5.00 +425.9%	-26.3%	$19.53M	N/A	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. ALLR, CLRB, LPCN, RKTO, and CELU

How does Heatwurx compare to Allarity Therapeutics?

Summary

How does Heatwurx compare to Cellectar Biosciences?

Summary

How does Heatwurx compare to Lipocine?

Summary

How does Heatwurx compare to Rocket One Inc. Common Stock?

Summary

How does Heatwurx compare to Celularity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. ALLR, CLRB, LPCN, RKTO, and CELU

How does Heatwurx compare to Allarity Therapeutics?

Does the media favor ALLR or PCSA?

Which has higher earnings and valuation, ALLR or PCSA?

Do insiders and institutionals have more ownership in ALLR or PCSA?

Do analysts rate ALLR or PCSA?

Is ALLR or PCSA more profitable?

Which has more volatility & risk, ALLR or PCSA?

Summary

How does Heatwurx compare to Cellectar Biosciences?

Do analysts rate PCSA or CLRB?

Is PCSA or CLRB more profitable?

Do insiders & institutionals believe in PCSA or CLRB?

Which has higher valuation and earnings, PCSA or CLRB?

Does the media prefer PCSA or CLRB?

Which has more volatility and risk, PCSA or CLRB?

Summary

How does Heatwurx compare to Lipocine?

Is PCSA or LPCN more profitable?

Does the media prefer PCSA or LPCN?

Do analysts prefer PCSA or LPCN?

Which has more risk & volatility, PCSA or LPCN?

Which has preferable valuation and earnings, PCSA or LPCN?

Do institutionals & insiders believe in PCSA or LPCN?

Summary

How does Heatwurx compare to Rocket One Inc. Common Stock?

Does the media prefer PCSA or RKTO?

Which has stronger earnings & valuation, PCSA or RKTO?

Do institutionals and insiders believe in PCSA or RKTO?

Is PCSA or RKTO more profitable?

Which has more volatility & risk, PCSA or RKTO?

Do analysts prefer PCSA or RKTO?

Summary

How does Heatwurx compare to Celularity?

Which has more risk & volatility, CELU or PCSA?

Does the media favor CELU or PCSA?

Do analysts rate CELU or PCSA?

Do insiders and institutionals have more ownership in CELU or PCSA?

Is CELU or PCSA more profitable?

Which has higher valuation and earnings, CELU or PCSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools